Bryostatin 1 induces productive Epstein-Barr virus replication in latently infected cells: implications for use in immunocompromised patients.
AffiliationCRC Department of Molecular Biology, Paterson Institute for Cancer Research, Christie CRC Cancer Centre, Manchester, UK.
MetadataShow full item record
AbstractBryostatin 1 is a novel anti-tumor agent currently undergoing clinical trial. We investigated the effect of this drug on B-lymphocyte cell lines that carry the Epstein-Barr virus and found that it induces these latently infected cells into the production of transforming virus particles over a wide range of concentrations. These results may have clinical implications, particularly with regard to the use of the drug in the immunocompromised patient.
CitationBryostatin 1 induces productive Epstein-Barr virus replication in latently infected cells: implications for use in immunocompromised patients. 1993, 33 (1):89-91 Cancer Chemother. Pharmacol.
JournalCancer Chemotherapy and Pharmacology
- Calcium modulation activates Epstein-Barr virus genome in latently infected cells.
- Authors: Faggioni A, Zompetta C, Grimaldi S, Barile G, Frati L, Lazdins J
- Issue date: 1986 Jun 20
- Cocaine potentiates the switch between latency and replication of Epstein-Barr virus in Raji cells.
- Authors: Di Francesco P, Lisi A, Rieti S, Manni V, Grimaldi S, Garaci E
- Issue date: 1999 Oct 14
- Bryostatins selectively regulate protein kinase C-mediated effects on GH4 cell proliferation.
- Authors: Mackanos EA, Pettit GR, Ramsdell JS
- Issue date: 1991 Jun 15
- Co-induction of lymphokine synthesis by the antineoplastic bryostatins.
- Authors: Mohr H, Pettit GR, Plessing-Menze A
- Issue date: 1987 Nov
- Spontaneous outgrowth of Epstein-Barr virus-positive B-cell lines from circulating human B cells of different buoyant densities.
- Authors: Yao QY, Czarnecka H, Rickinson AB
- Issue date: 1991 May 10